These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31537731)

  • 21. The Origins of "Confidential Commercial Information" at the FDA.
    Daval CJR; Kesselheim AS
    JAMA; 2024 Aug; 332(7):533-534. PubMed ID: 39037797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Safe Medical Devices Act of 1990--FDA. Notice.
    Fed Regist; 1991 Apr; 56(66):14111-3. PubMed ID: 10111151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 25. Disclosure of cigarette ingredients: potential domino effect?
    Buasai S
    Southeast Asian J Trop Med Public Health; 1994 Dec; 25(4):613-4. PubMed ID: 7667700
    [No Abstract]   [Full Text] [Related]  

  • 26. [Health inspection and the development of food control in Stockholm, 1878-1912].
    Ramme U
    Hist Tidskr; 2001; (4):571-94. PubMed ID: 18437772
    [No Abstract]   [Full Text] [Related]  

  • 27. Advancing FDA's regulatory science through weight of evidence evaluations.
    Cormier JW
    J Contemp Health Law Policy; 2011; 28(1):1-22. PubMed ID: 22292318
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The plastic panic: how worried should we be about everyday chemicals?
    Groopman J
    New Yorker; 2010 May; ():26-31. PubMed ID: 21695842
    [No Abstract]   [Full Text] [Related]  

  • 30. Dealing with tobacco--the implications of a legislative settlement with the tobacco industry.
    Warner KE
    Am J Public Health; 1997 Jun; 87(6):906-9. PubMed ID: 9224165
    [No Abstract]   [Full Text] [Related]  

  • 31. Tobacco product regulation--a public health approach.
    Deyton L; Sharfstein J; Hamburg M
    N Engl J Med; 2010 May; 362(19):1753-6. PubMed ID: 20410498
    [No Abstract]   [Full Text] [Related]  

  • 32. Obesity--the new frontier of public health law.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2006 Jun; 354(24):2601-10. PubMed ID: 16775242
    [No Abstract]   [Full Text] [Related]  

  • 33. Anton J. Carlson: witness for the prosecution.
    Young JH
    Pharm Hist; 1999; 41(2):47-51. PubMed ID: 11623946
    [No Abstract]   [Full Text] [Related]  

  • 34. An early historical perspective on the FDA's regulation of OTC drugs.
    Bruch MK; Larson E
    Infect Control Hosp Epidemiol; 1989 Nov; 10(11):527-8. PubMed ID: 2685103
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA reorganization.
    Weissinger J
    J Parenter Sci Technol; 1988; 42(4):122-6. PubMed ID: 3054036
    [No Abstract]   [Full Text] [Related]  

  • 36. Food and Drug Administration: 100 years of protection.
    Mosocco DJ
    Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704
    [No Abstract]   [Full Text] [Related]  

  • 37. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
    Huh J; DeLorme DE; Reid LN; An S
    Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
    Abraham J; Davis C
    Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA's Kessler stays, NIH's Healy goes.
    Greenberg DS
    Lancet; 1993 Mar; 341(8846):681-2. PubMed ID: 8095583
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical Ethics and Grassroots Activism in the United States: A Social History Perspective.
    Batt S; Butler J; Shannon O; Fugh-Berman A
    J Bioeth Inq; 2020 Mar; 17(1):49-60. PubMed ID: 31953647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.